NASDAQ:CTSO - Cytosorbents Stock Price, Forecast & News

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Cytosorbents Corp (NASDAQ:CTSO) released its quarterly earnings data on Tuesday, November, 5th. The medical research company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.08. The medical research company had revenue of $6.10 million for the quarter, compared to analysts' expectations of $6.49 million. Cytosorbents had a negative net margin of 87.79% and a negative return on equity of 165.00%. View Cytosorbents' Earnings History.

Cytosorbents is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cytosorbents.

Cytosorbents updated its fourth quarter 2019 IntraDay earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.4-7.4 million, compared to the consensus revenue estimate of $6.71 million.

3 Wall Street analysts have issued 1-year price targets for Cytosorbents' shares. Their forecasts range from $8.00 to $13.00. On average, they expect Cytosorbents' stock price to reach $11.00 in the next year. This suggests a possible upside of 67.7% from the stock's current price. View Analyst Price Targets for Cytosorbents.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents.

News headlines about CTSO stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytosorbents earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Cytosorbents.

Some companies that are related to Cytosorbents include LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), Alphatec (ATEC), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Restoration Robotics (HAIR), SeaSpine (SPNE), Iradimed (IRMD), Accuray (ARAY) and Repro-Med Systems (REPR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Micron Technology (MU), Eyepoint Pharmaceuticals (EYPT), Zynerba Pharmaceuticals (ZYNE), Aethlon Medical (AEMD), Sorrento Therapeutics (SRNE) and MEI Pharma (MEIP).

Cytosorbents' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (1.70%), Geode Capital Management LLC (1.11%), Sargent Investment Group LLC (0.82%), Sargent Investment Group LLC (0.72%), Raymond James & Associates (0.44%) and Bank of New York Mellon Corp (0.37%). Company insiders that own Cytosorbents stock include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.

CTSO stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Sargent Investment Group LLC, Sargent Investment Group LLC, Bradley Foster & Sargent Inc. CT, Charles Schwab Investment Management Inc., New York State Common Retirement Fund, Victory Capital Management Inc. and Bank of America Corp DE. View Insider Buying and Selling for Cytosorbents.

CTSO stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Winning Points Advisors LLC, Goldman Sachs Group Inc., UBS Group AG, Spark Investment Management LLC, Barclays PLC, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch and Phillip P Chan. View Insider Buying and Selling for Cytosorbents.

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTSO stock can currently be purchased for approximately $6.56.

Cytosorbents has a market capitalization of $212.68 million and generates $22.50 million in revenue each year. The medical research company earns $-17,210,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.View Additional Information About Cytosorbents.

The official website for Cytosorbents is http://www.cytosorbents.com/.

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]